POL6326

DRUG6 trials

Sponsors

Polyphor Ltd., MedSIR

Conditions

Acute Myeloid Leukemia in RemissionAdult Acute Lymphoblastic Leukemia in RemissionAdvanced Breast CancerChronic Lymphocytic Leukemia (CLL)Chronic Myelogenous Leukemia (CML)HealthyLarge Reperfused ST-Elevation Myocardial InfarctionMetastatic Breast Cancer

Phase 1

Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies

CompletedNCT01413568

Polyphor Ltd.Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Remission, Chronic Lymphocytic Leukemia (CLL) +5

Start: 2012-04-30End: 2015-12-31Updated: 2016-02-26

Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer

CompletedNCT01837095

Polyphor Ltd.Metastatic Breast Cancer

Start: 2013-06-30End: 2018-08-31Updated: 2018-09-14

Safety and Efficacy of POL6326 for Mobilization of Hematopoietic Stem Cells in Healthy Volunteers

CompletedNCT01841476

Polyphor Ltd.Healthy

Start: 2012-02-29End: 2015-09-30Updated: 2015-11-25

POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer

WithdrawnNCT04826016

MedSIRAdvanced Breast Cancer

Start: 2022-03-16End: 2022-03-16Updated: 2023-03-20

Phase 2

Exploratory Study on POL6326 in Stem Cell Mobilization

CompletedNCT01105403

Polyphor Ltd.Multiple Myeloma

Start: 2009-04-30End: 2014-04-30Updated: 2014-04-23

CXCR4 Antagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI)

CompletedNCT01905475

Polyphor Ltd.Large Reperfused ST-Elevation Myocardial Infarction

Start: 2013-07-31End: 2016-06-30Updated: 2016-06-10

Related Papers

Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives.

2022-11-24186 citations

Abstract 414: Efficacy of Balixafortide (POL6326) and Paclitaxel alone and in combination in humanized breast cancer PDX

Cancer Research2021-07-012 citations

Balixafortide (a CXCR4 antagonist) plus eribulin in HER2 negative metastatic breast cancer: Dose-response analysis of efficacy from phase I single-arm trial.

Journal of Clinical Oncology2020-05-203 citations

Abstract A003: Anti-angiogenic activity of the CXCR4 antagonist balixafortide

Molecular Cancer Therapeutics2019-12-012 citations

Abstract 3965: Circulating levels of IFN gammaand neutrophil counts in breast cancer patients who received balixafortide and eribulin combination therapy

Clinical Research (Excluding Clinical Trials)2019-07-01

Abstract 3965: Circulating levels of IFN gammaand neutrophil counts in breast cancer patients who received balixafortide and eribulin combination therapy

Cancer Research2019-07-01

Balixafortide (a CXCR4 antagonist) + eribulin in HER2-negative metastatic breast cancer (MBC): Survival outcomes of the phase I trial.

Journal of Clinical Oncology2019-05-203 citations

Balixafortide (a novel CXCR4 inhibitor) and eribulin in HER2-neg metastatic breast cancer (MBC) patients (pts): A phase I trial

Annals of Oncology2018-10-01

Pharmacology, ADME and selectivity profile of the next generation CXCR4 antagonist balixafortide.

Journal of Clinical Oncology2018-05-203 citations

Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.

2018-04-26111 citations

Phase I study of the combination of balixafortide (CXCR4 inhibitor) and eribulin in HER2-negative metastatic breast cancer (MBC) patients (pts).

Journal of Clinical Oncology2017-05-204 citations

Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial

Journal of Translational Medicine2017-01-0347 citations

Dose escalation of POL6326 in combination with eribulin in HER2-negative relapsed metastatic breast cancer (mBCa) patients (pts).

Journal of Clinical Oncology2016-05-20